A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis

Summary

This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with mild to moderate atopic dermatitis.

Timeline

Start

2023-06-10

Primary completion

2024-12-13

Completion

2025-08-15

Drugs

Indications